Researchers unlock new insights into hard-to-treat neuroendocrine tumors

Researchers at Boston Medical Center and Dana-Farber Cancer Institute conducted one of the first-ever analyses of neuroendocrine tumors (NETs) at single cell resolution, unlocking new insights into this rare and often hard-to-treat cancer.

Cognitive impairment following SARS-CoV-2 infection: study adds to existing evidence, but finds important exceptions

A new study evaluated the presence, magnitude, persistence, and correlations of effects in community-based cases.

July 25, 2023

Rapamycin shows promise in slowing Alzheimer’s disease progression linked to seizures

Protein imbalances that increase brain cell excitability may explain why individuals with Alzheimer’s disease (AD) who also experience seizures demonstrate more rapid cognitive decline than

May 2, 2024

Potentially Protective Agent Shows Benefit in Niemann-Pick Type C

Patients with Niemann-Pick disease type C who received N-acetyl-L-leucine (NALL), an agent that potentially ameliorates lysosomal and metabolic dysfunction, showed reduced neurologic signs and symptoms

February 1, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.